Please login to the form below

GLP-1 agonists

This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus

Drug is first and so far only oral alternative to injectable GLP-1 agonists. ... February. Rybelsus is the first and so far only oral alternative to injectable GLP-1 agonists such as Eli Lilly’s Trulicity (dulaglutide) and Novo Nordisk’s Ozempic

Latest news

Lilly’s Trulicity scores CV reduction indication in the US

The once-weekly GLP-1 agonist has been available in the US since 2014, when it first gained FDA approval to improve glycaemic control in adults with type 2 diabetes. ... The new MACE approval could help Lilly in its fight for market share with other
Novo bolstered by new diabetes, obesity products

The once-weekly injectable GLP-1 agonist has continued to offset declines of Novo’s older drugs, including the one-daily shot Victoza (liraglutide). ... It is the first oral alternative to injectable GLP-1 agonists, and has also been touted by Novo as
Novo Nordisk gets FDA okay for new diabetes hope

Potential to combat increasing competition and pricing pressures. Novo Nordisk has FDA approval for the first oral alternative to injectable GLP-1 agonists, which the company thinks could be a blockbuster ... product. The US regulator has approved the
Novo Nordisk shareholder revolt reaches Europe

Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.
Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

Lilly revealed last November that the top-line data with the once-weekly GLP-1 agonist was positive, and over the weekend at the American Diabetes Association meeting, presented the detailed ... Trulicity's growth to date has stemmed largely from its once

More from news
Approximately 8 fully matching, plus 40 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

Upon interaction with the GLP-1 receptor, it stimulates the secretion of insulin in a glucose-dependent manner. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2,
Deal Watch table for January 2015

Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in